RecruitingEarly Phase 1NCT07717346

A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease

An Open-Label Study to Investigate Safety and Preliminary Efficacy of KB111 for the Treatment of Hailey-Hailey Disease

Sponsor

Krystal Biotech, Inc.

Enrollment

7 participants

Start Date

May 6, 2026

Study Type

INTERVENTIONAL

Conditions

Skin Diseases Hailey Hailey Disease Lesion Skin

Summary

An open-label study to evaluate the safety and efficacy of KB111 in pediatric and adult subjects with Hailey-Hailey Disease

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called KB111 for people with hailey hailey disease, lesion skin, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALKB111

KB111 is a replication-defective, non-integrating herpes simplex virus (HSV-1)-based vector encoding functional, full-length human ATP2C1 protein combined with a gel for topical application.